The purpose of this study was to correlate bleeding complications during and after treatment with recombinant tissue-type plasminogen activator (rt-PA) 
dial infarction has been shown to lyse coronary thrombi,1-5 improve left ventricular function,6-8 and reduce mortality. 8 The use of intravenous rt-PA in combination with heparin, however, is associated with a variable, although usually moderate, degree of systemic fibrinolytic activation and fibrinogen breakdown9'10 and with a bleeding tendency.11 "12 Bleeding in patients treated with rt-PA correlates only weakly with the extent of fibrinogen degradation13 and with the increase of fibrinogen degradation products in serum. 10 In the present study, we investigated the correlation of spontaneous and intervention-related bleeding during thrombolytic therapy with rt-PA with clinical and laboratory measurements of hemosta-sis. The hemostasis parameters included template bleeding time, ADP-induced platelet aggregation, fibrinogen and rt-PA levels, dose and duration of rt-PA infusion, and serum levels of fibrinogen degradation products. Methods 
Patient Selection Criteria
The present investigation was carried out as an ancillary study to ongoing protocols on the efficacy of alternative rt-PA administration schemes for early and late coronary artery recanalization as evaluated by coronary angiography. Fifty-two of 55 consecutive patients were entered into the study between January 1987 and October 1988. The criteria for admission to the study were as follows: 1) chest pain suggestive of acute myocardial infarction of at least 30 minutes duration within 6 hours from onset, 2) acute "transmural" myocardial infarction with ST-segment elevation of at least 0.1 mV in two adjacent standard electrocardiographic leads, 3) age less than 70 years, and 4) no contraindications to thrombolytic therapy.
Exclusion criteria included previous infarction in the same myocardial zone, cardiogenic shock (systolic blood pressure of less than 90 mm Hg with signs of systemic hypoperfusion), recent cardiopulmonary resuscitation, left bundle branch block, blood pressure of 180/110 mm Hg or more despite initial therapy, recent bleeding, surgery within the previous 21 days, advanced complicating disease, history of cerebrovascular disease, head or spinal trauma within 6 months, clouded sensorium, or child-bearing potential. Three patients with baseline template bleeding times of more than 9.5 minutes who fulfilled the other entry criteria, were not treated with rt-PA because of concern that they might be at greater risk of bleeding.
Fourteen patients had taken aspirin within 48 hours before entry into the study. Written informed consent was obtained from each patient. The study design was approved by the hospital committee for human studies, and the rt-PA was administered as an "investigational new drug" under the regulations established by the US Food and Drug Administration.
Study Protocol
Patients received standard therapy for myocardial infarction in the emergency room, including sublingual nitroglycerin, intravenous morphine sulfate (5-10 mg), intravenous lidocaine (1-2 mg/min), and oxygen (2 1/min). After initial blood sampling and template bleeding time determination, heparin (5,000 U) was given as an intravenous bolus. The patients were treated with rt-PA (Activase, Genentech Inc, South San Francisco, California) for myocardial infarction according to one of four protocols: 1) 1 mg/kg over 90 minutes (nine patients); 2) 60 mg for 1 hour, 20 mg for 1 hour, 5 mg/hr for 4 hours for 100 mg total (13 patients); 3) 1 mg/kg over 90 minutes followed by 0.2 mg/kg/hr for 2.5 hours to a maximum of 120 mg (22 patients); or 4) 1 mg/kg over 90 minutes followed by 0.2 mg/kg/hr for 4 hours (eight patients).
Ninety minutes after the beginning of the rt-PA infusion and immediately after vascular sheaths were placed for cardiac catheterization, a maintenance infusion of heparin was begun, continued for 10 days, and adjusted to prolong the partial thromboplastin time to 1.5 to 2 times control. All patients were treated with intravenous nitroglycerin as tolerated by blood pressure. Patients underwent cardiac catheterization within 90 minutes of onset of the thrombolytic therapy, and repeat coronary angiography of the infarct-related artery was performed at 150 minutes to determine coronary patency. Patients with recurrent chest pain and/or ST elevations were returned to the catheterization laboratory for repeat coronary angiography. Within 7 to 10 days all patients with patent infarct-related arteries on initial angiography underwent repeat coronary angiography to determine vessel patency. Patients were maintained on intravenous lidocaine and treated with oral diltiazem during the inhospital period in the absence of contraindications.
Hemostasis Analyses
All patients were closely monitored in the catheterization laboratory and coronary care unit for evidence of spontaneous or intervention-related bleeding episodes. Bleeding events occurring within 5 days of rt-PA therapy were prospectively defined and classified into three mutually exclusive groups, with assignment to the group with the highest number as follows:
Grade upper arm was inflated to 40 mm Hg, the bleeding time was performed distal to and parallel with the antecubital crease.14 Bleeding times were performed in an area of the forearm free of blood vessels and were not performed proximal to intravenous infusion sites. Blood from the wound was blotted every 30 seconds (being careful not to disturb the wound itself) until the wound was dry.
Venous blood samples for fibrinogen, activated partial thromboplastin time, and ADP-induced platelet aggregation were collected into trisodium citrate (final concentration, 0.01 M) containing 200 KIU/ml aprotinin (Sigma, St. Louis, Missouri) at the same time points. Platelet counts were performed with an automatic particle counter (Coulter, Hialeah, Florida) on blood drawn into EDTA. Platelet-rich plasma was prepared by centrifugation for 3 minutes at 800g. Plasma for the other studies was obtained from blood samples kept on ice until the end of the experiment, then centrifuged at 3,000g for 10 minutes, and stored at -20°C.
Fibrinogen was measured with a clotting rate assay (Clauss method)15 as modified. '6 This assay is insensitive to therapeutic concentrations of heparin. Rt-PA-related antigen levels,17 fibrinogen degradation products,'8 and platelet aggregation19 were measured as previously described. Maximum platelet aggregation was determined as the percent change in transmittance (,AT) from baseline to the lowest portion of the curve. The difference between baseline values and values obtained at 90 minutes (using the same concentration ofADP) was tabulated. Activated partial thromboplastin time was measured conventionally by the hospital clinical laboratory.
Statistical Analysis
Student's t test for paired or unpaired values was used to evaluate two-tailed levels of significance of differences within or between groups of patients. For variables that were not normally distributed, a Mann-Whitney test was used. The significance of differences between groups was analyzed using Fisher's or Kruskal-Wallis (for ordered categoric data) exact tests. Values expressed represent medians with ranges for non-normally distributed data or mean±SDS for normally distributed data. Ninetyfive percent confidence intervals are given for sensitivity and specificity of a prolonged bleeding time at 90 minutes (.9 minutes) as a predictor of spontaneous bleeding. A multivariate model for correlates of spontaneous bleeding was selected using exact logistic regression.20 All variables in Table 1 were used for selecting the best set of correlate variables for the logistic model. All correlates were transformed into one or more indicator variables (value 0 or 1) and included in the model. The final model was chosen by a stepwise selection procedure that only retained significant variables.
Results Fifty-two patients with acute, transmural myocardial infarction were treated with rt-PA. The clinical and laboratory parameters in the patient groups are summarized in Table 1 . Thirteen patients had documented spontaneous clinical bleeding (grade 2 bleeding) including oral mucosal bleeding (six patients), epistaxis (two), unprovoked hematoma (two), hematemesis (one), external ear bleeding (one), and bleeding from a psoriatic patch (one). In addition, 11 patients developed intervention-related groin hematoma for which one patient required transfusion of 2 units of packed red cells. No intracerebral bleeding was documented. All episodes of bleeding were seen within 48 hours of thrombolytic therapy.
Bleeding times were measured prior to therapy and after 90 minutes in all patients. In addition, a 4-hour bleeding time was measured in the final 35 patients. The bleeding time prolonged from a mean value of 5.0±1.9 minutes at baseline to 8.2+4.3 minutes after 90 minutes (p<0.0001, Table 1 ), with 14 of 52 patients (27%) having bleeding times greater than 9.0 minutes at 90 minutes compared with only one of 52 (2%) at the baseline examination. At 4 hours the bleeding time was shorter than at 90 minutes: in the 35 patients with available data at both time points, it had decreased from a median of 8.0 minutes at 90 minutes to 7.0 minutes at 4 hours (p<0.05), with only seven of 35 patients (20%) having bleeding times greater than 9 minutes. Thus, intravenous rt-PA prolongs the bleeding time during administration of the initial thrombolytic dose of rt-PA, but the bleeding time shortens significantly during the following 2.5 hours (Figure 1) . The significant correlations of spontaneous bleeding or decrease in hematocrit with the clinical and laboratory parameters are summarized in Table 2 Discussion Bleeding constitutes the main side effect of thrombolytic therapy. The extensive experience with streptokinase and the more recent experience with more fibrin-specific thrombolytic agents including rt-PA have revealed that although severe hypofibrinogenemia does predispose to bleeding,10,13 there is only a weak correlation between the extent of fibrinogen breakdown and the occurrence of bleeding. Bleeding most frequently occurred in association with vascular puncture or other invasive procedures, suggesting that vascular injury constitutes the main pathogenetic mechanism. Consequently, bleeding may be circumvented to a significant extent by careful patient selection and by avoiding vascular puncture.
Despite these precautions spontaneous bleeding (including intracranial bleeding) may occur unexpectedly, even in carefully selected patients. A frequency of cerebral bleeding of 1.6% was reported in 1,014 patients treated with 150 mg of rt-PA. 12 The frequency was reduced to 0.6% in 1,452 patients treated with 100 mg of rt-PA and to 0.4% in 3,768 patients who received 80-120 mg of rt-PA, suggesting a dose-response relation. 21 Neurologic events in studies with streptokinase have usually been reported as strokes without careful differential diagnosis between thrombotic and hemorrhagic events and have ranged in large studies between 0.8% and 1.1%.22,23 From a theoretic point of view, rt-PA, which is a more effective thrombolytic agent for coronary thrombolysis, might also cause more effective dissolution of hemostatic plugs, but the increased risk of bleeding might be partially or totally offset by a lesser derangement of the hemostatic system and less interference with the formation of hemostatic plugs. If this hypothesis is correct, the most severe bleeding would be expected to occur in patients in whom a critical hemostatic plug of a vascular lesion is dissolved during thrombolytic therapy in the setting of severe hypofibrinogenemia and adjunctive anticoagulant or antiplatelet therapy. Evaluation of this hypothesis will require quantitative parameters for the assessment of a tendency to bleeding which closely correlate with spontaneous bleeding. Serial template bleeding time measurements might provide such a parameter.
In the present study 52 consecutive patients presenting with acute transmural myocardial infarction and a normal baseline template bleeding time (c9 minutes) were treated with rt-PA and monitored with serial template bleeding time measurements. No major or life-threatening bleeding occurred, but 13 demonstrated by routine analysis did not identify major correlates of spontaneous bleeding. However, the present pilot study in a small number of patients has only limited statistical power, and our failure to find significant correlations between bleeding and other clinical and laboratory parameters could well be due to beta-type error. On the other hand, the extensive experience with thrombolytic therapy with both streptokinase and rt-PA in many large-scale clinical trials has also not revealed any parameter which predicts spontaneous bleeding with a clinically useful sensitivity or specificity. Thus, prolongation of the bleeding time appears to be the first recognized, potentially useful index for identifying and possibly quantitating the bleeding tendency associated with thrombolytic therapy.
The demonstration of an interactive effect of aspirin and rt-PA on prolongation of the template bleeding time and on spontaneous bleeding has prompted experimental studies in animal models.26,27
The first study in a blinded, randomized, placebocontrolled experimental design has confirmed that pretreatment with aspirin causes both a marked bleeding tendency and prolongation of the bleeding time during infusion of rt-PA at doses which do not prolong the bleeding time when given alone. 26 The second study in rabbits has confirmed these observations and, furthermore, has demonstrated that intravenous administration of recombinant plasminogen activator inhibitor-1 instantly reverses both the bleeding diathesis and the bleeding time prolongation.27 These studies thus confirm the major finding of the current investigation, namely, that the bleeding diathesis can be identified by the template bleeding time. The mechanism of the prolongation of the bleeding time is not obvious, but its rapid reversibility with plasminogen activator inhibition would argue against slowly reversible mechanisms such as depletion of plasma proteins or degradation of platelet receptors. Instead, the reversibility of this phenomenon is suggestive of plasmin-mediated derangement of platelet aggregation which cannot be identified with ADP-induced platelet aggregation studies. The fact that the bleeding time remained normal (less than 9 minutes) in about two of three patients in this study in which the coronary patency rate at 90 minutes was 44 out of 51 (86%) suggests that it is not necessary to prolong the bleeding time in order to achieve thrombolysis and is indicative of the thrombus selectivity of rt-PA. It may become possible to optimize thrombus specificity either by modification of the administration scheme of rt-PA or by altering the adjuvant therapy. Alternatively, it might be possible to change the t-PA molecule by recombinant DNA techniques such that its interference with blood platelets and the vessel wall is decreased or its fibrin affinity is increased. Serial bleeding time measurements may be useful for the investigation of such strategies.
It is concluded that the template bleeding time may constitute a useful quantitative index of the hemorrhagic diathesis occurring in some patients during thrombolytic therapy with rt-PA and that it may represent a useful parameter for the investigation of the occurrence and mechanism of spontaneous bleeding. If confirmed in large prospective studies, prolongation of the bleeding time might be useful for the early detection of an increased bleeding risk, potentially allowing appropriate changes in the dose and duration of rt-PA therapy.
